Vipadenant
Selleck Chemicals
SKU:E7944
Couldn't load pickup availability

Vipadenant is an antagonist of Adenosine Receptors used in studies of GPCR Signaling. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to receptor-driven second-messenger signaling and desensitization dynamics in cardiovascular and inflammation models.
By blocking Adenosine Receptors, Vipadenant can be used to examine receptor-driven second-messenger signaling and desensitization dynamics. The gpcr annotation adds relevance to GPCR pharmacology, ligand-binding, and signaling assays, together with downstream-response mapping in the same experimental setting. In cardiovascular and inflammation models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.
Research Applications
- Target-focused assays involving Adenosine Receptors
- Pathway perturbation studies connected to GPCR Signaling
- Receptor-blockade and ligand-competition studies
- GPCR pharmacology, ligand-binding, and signaling assays
Overall, Vipadenant is appropriate when a defined chemical perturbant is needed to connect Adenosine Receptors with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cardiovascular and inflammation models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Targets:
- Adenosine Receptors
- Target Class:
- GPCR
- Pathways:
- GPCR Signaling
- Research Area:
- Cardiovascular • Inflammation
- CAS No.:
- 442908-10-3
- Molecular Weight:
- 321.34
- PubChem:
- 21874557
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.